Morphic Holding IncNASDAQ:MORF
- LAST PRICE28.5600
- TODAY'S CHANGE (%)0.0600 (0.2105%)
- Bid / Lots28.5400/ 1
- Ask / Lots28.5700/ 1
- Open / Previous Close28.4100 / 28.5000
- Day Range
- 52 Week Range
- Volume241,576
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MORF |
|---|---|---|
| 09:32 ET | 1904 | 28.41 |
| 09:41 ET | 100 | 28.38 |
| 09:43 ET | 500 | 28.91 |
| 09:54 ET | 100 | 29.05 |
| 10:03 ET | 100 | 29.09 |
| 10:06 ET | 600 | 29.11 |
| 10:08 ET | 800 | 28.99 |
| 10:10 ET | 300 | 29.08 |
| 10:12 ET | 836 | 28.96 |
| 10:14 ET | 800 | 28.9 |
| 10:15 ET | 200 | 28.95 |
| 10:17 ET | 845 | 28.955 |
| 10:19 ET | 1919 | 28.97 |
| 10:21 ET | 896 | 28.95 |
| 10:24 ET | 100 | 28.9 |
| 10:26 ET | 700 | 28.73 |
| 10:30 ET | 600 | 28.84 |
| 10:32 ET | 100 | 28.8 |
| 10:33 ET | 200 | 28.95 |
| 10:35 ET | 310 | 28.95 |
| 10:39 ET | 1213 | 28.91 |
| 10:44 ET | 400 | 28.85 |
| 10:46 ET | 600 | 28.8 |
| 10:48 ET | 191 | 28.84 |
| 10:50 ET | 4280 | 29.04 |
| 10:51 ET | 2298 | 28.99 |
| 10:53 ET | 100 | 28.86 |
| 10:55 ET | 704 | 28.8 |
| 10:57 ET | 200 | 28.81 |
| 11:00 ET | 300 | 28.75 |
| 11:02 ET | 300 | 28.73 |
| 11:04 ET | 400 | 28.75 |
| 11:06 ET | 1300 | 28.775 |
| 11:08 ET | 200 | 28.85 |
| 11:09 ET | 619 | 28.94 |
| 11:11 ET | 100 | 28.95 |
| 11:13 ET | 1000 | 28.9 |
| 11:20 ET | 400 | 28.88 |
| 11:22 ET | 300 | 28.79 |
| 11:26 ET | 500 | 28.84 |
| 11:27 ET | 408 | 28.83 |
| 11:29 ET | 100 | 28.86 |
| 11:31 ET | 300 | 28.865 |
| 11:33 ET | 100 | 28.91 |
| 11:36 ET | 5276 | 28.76 |
| 11:38 ET | 147489 | 28.53 |
| 11:40 ET | 600 | 28.63 |
| 11:42 ET | 100 | 28.62 |
| 11:45 ET | 900 | 28.62 |
| 11:49 ET | 100 | 28.625 |
| 11:51 ET | 1800 | 28.59 |
| 11:56 ET | 200 | 28.699 |
| 11:58 ET | 2300 | 28.505 |
| 12:02 ET | 100 | 28.48 |
| 12:03 ET | 3342 | 28.55 |
| 12:05 ET | 400 | 28.54 |
| 12:07 ET | 1900 | 28.49 |
| 12:12 ET | 400 | 28.42 |
| 12:14 ET | 200 | 28.46 |
| 12:20 ET | 200 | 28.45 |
| 12:21 ET | 400 | 28.32 |
| 12:23 ET | 300 | 28.25 |
| 12:25 ET | 685 | 28.3 |
| 12:30 ET | 315 | 28.28 |
| 12:34 ET | 300 | 28.32 |
| 12:41 ET | 300 | 28.37 |
| 12:52 ET | 100 | 28.375 |
| 12:54 ET | 1300 | 28.385 |
| 12:56 ET | 600 | 28.4 |
| 12:57 ET | 200 | 28.45 |
| 01:01 ET | 200 | 28.4 |
| 01:03 ET | 300 | 28.44 |
| 01:06 ET | 1012 | 28.63 |
| 01:19 ET | 122 | 28.7 |
| 01:24 ET | 100 | 28.605 |
| 01:26 ET | 100 | 28.625 |
| 01:28 ET | 428 | 28.57 |
| 01:30 ET | 105 | 28.56 |
Apr 16, 2024
Apr 15, 2024
Apr 11, 2024
Apr 10, 2024
MORF NEWS: Johnson Fistel has Commenced an Investigation on Behalf of Morphic Holding Company Shareholders, from 11:32AM ET on Wednesday Apr 10, 2024 by Dow Jones
11:32AM ET on Wednesday Apr 10, 2024 by Dow Jones
Apr 9, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Morphic Holding Inc | 1.4B | -8.2x | --- |
Akero Therapeutics Inc | 1.4B | -7.4x | --- |
Edgewise Therapeutics Inc | 1.4B | -10.0x | --- |
Kura Oncology Inc | 1.4B | -9.1x | --- |
Gyre Therapeutics Inc | 1.4B | -0.8x | --- |
Day One Biopharmaceuticals Inc | 1.3B | -6.4x | --- |
Company Information
Morphic Holding, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company’s Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The Company is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). It has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.
Contact Information
- Headquarters
- 35 GATEHOUSE DRIVE A2WALTHAM, MA, United States 02451
- Phone
- 781-996-0955
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Gustav Christensen
- President
- Bruce Rogers
- Chief Executive Officer, Director
- Praveen Tipirneni
- Chief Financial Officer, Chief Operating Officer
- Marc Schegerin
- Senior Vice President - Finance, Chief Accounting Officer
- Robert Farrell
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4B |
|---|---|
Revenue (TTM) | $521.0K |
Shares Outstanding | 50.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.47 |
EPS | $-3.49 |
Book Value | $14.01 |
P/E Ratio | -8.2x |
Price/Sales (TTM) | 2,737.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -34,296.74% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
